DBVT DBV Technologies S.A. - American Depositary Shares
About DBV Technologies S.A. - American Depositary Shares Company overview from Wikipedia
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Read more
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
History
DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
DBVT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
DBVT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
DBVT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 3 37.5%
- Buy 3 37.5%
- Hold 1 12.5%
- Sell 1 12.5%
- Strong Sell 0 0.0%
12-Month Price Target
6 analysts · 2026-08-17Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.12 | $-0.10 | -0.02% |
| March 31, 2026 | $-0.11 | $-0.08 | -0.03% |
| Dec. 31, 2025 | $-0.23 | $-0.11 | -0.12% |
| Sept. 30, 2025 | $-0.24 | $-0.25 | 0.01% |
| June 30, 2025 | $-0.31 | $-0.33 | 0.02% |
| June 30, 2024 | $-0.34 | $-0.20 | -0.14% |
| March 31, 2024 | $-0.28 | $-0.31 | 0.03% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 13
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M | $11M | $15M | |
| R&D Expense | $117M | $89M | $60M | $76M | $70M | $102M | $115M | |
| SG&A Expense | $33M | $29M | $30M | $24M | $31M | $35M | $49M | |
| Operating Expenses | $153M | $121M | $92M | $101M | $104M | $170M | $186M | |
| Operating Income | $-147M | $-117M | $-76M | $-97M | $-99M | $-159M | $-171M | |
| Pretax Income | $-146M | $-114M | $-73M | $-96M | $-98M | $-160M | $-171M | |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | $-381.0K | $-10.0K | $610.0K | |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M | $-160M | $-172M | |
| EPS (Basic) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| EPS (Diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| Shares (Basic) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| Shares (Diluted) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| EBITDA | · | · | $-76M | $-97M | $-99M | $-159M | · |
Balance Sheet 26
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194M | $32M | $141M | $209M | $77M | $196M | $193M | |
| Receivables | · | · | $0 | $0 | $0 | $2M | · | |
| Inventory | · | · | · | · | · | $0 | $2M | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $4M | $3M | $4M | |
| Other Current Assets | $19M | $12M | $18M | $14M | $37M | $9M | $9M | |
| Current Assets | $213M | $44M | $159M | $223M | $114M | $207M | $205M | |
| PP&E (Net) | $10M | $11M | $13M | $15M | $18M | $25M | $25M | |
| PP&E (Gross) | $33M | $29M | $32M | $30M | $32M | $41M | $36M | |
| Accum. Depreciation | $23M | $18M | $19M | $15M | $14M | $17M | $11M | |
| Intangibles | $0 | $40.0K | $58.0K | $10.0K | $22.0K | $41.0K | $48.0K | |
| Other Non-current Assets | $6M | $4M | $6M | $6M | $7M | $30M | $19M | |
| Total Assets | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Accounts Payable | $41M | · | · | · | · | · | · | |
| Current Liabilities | $58M | $31M | $37M | $30M | $31M | $53M | $54M | |
| Capital Leases | $5M | $6M | $5M | $1M | $7M | $10M | $22M | |
| Other Non-current Liabilities | · | $0 | $0 | $5M | $2M | $475.0K | $80.0K | |
| Total Liabilities | $65M | $38M | $43M | $52M | $47M | $67M | $79M | |
| Long-term Debt | · | · | · | · | $510.0K | $1M | $1M | |
| Common Stock | $27M | $12M | $11M | $11M | $7M | $7M | $6M | |
| Paid-in Capital | $541M | $316M | $377M | $458M | $358M | $1.15B | $1.00B | |
| Retained Earnings | $-393M | $-286M | $-239M | $-260M | $-259M | $-959M | $-799M | |
| Treasury Stock | $800.0K | $1M | $1M | $1M | $1M | $1M | $230.0K | |
| AOCI | $500.0K | $905.0K | $742.0K | $781.0K | $519.0K | $484.0K | $108.0K | |
| Stockholders' Equity | $169M | $27M | $140M | $194M | $99M | $205M | $193M | |
| Liabilities + Equity | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Shares Outstanding | · | 102,847,501 | · | · | 5,128,423 | 4,036,263 | 4,026,688 |
Cash Flow 12
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $4M | · | · | · | · | |
| Stock-based Comp | $5M | $5M | $6M | $5M | $3M | $-1M | $17M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | · | · | · | $0 | $24M | · | |
| Operating Cash Flow | $-121M | $-104M | $-80M | $-56M | $-108M | $-166M | $-148M | |
| CapEx | $532.0K | $2M | $677.0K | $754.0K | $910.0K | $3M | $6M | |
| Investing Cash Flow | $-1M | $-757.0K | $-808.0K | $-100.0K | $-433.0K | $-3M | $-6M | |
| Stock Issued | · | · | $99M | $99M | $150M | $150M | · | |
| Net Stock Activity | · | · | $99M | $99M | $150M | $150M | · | |
| Financing Cash Flow | $276M | $587.0K | $7M | $194M | $274.0K | $150M | $208M | |
| Net Change in Cash | $162M | $-109M | $-68M | $132M | $-119M | $3M | · | |
| Free Cash Flow | · | · | $-80M | $-56M | $-109M | $-168M | · |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| Net Margin | · | · | -462.4% | -1987.5% | -1713.5% | -1415.0% | · | |
| Pretax Margin | · | · | -462.4% | -1986.0% | -1720.2% | -1415.1% | · | |
| EBITDA Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| ROA | · | · | -33.9% | -49.0% | -46.7% | -58.7% | · | |
| ROE | · | · | -51.2% | -47.4% | -90.5% | -72.8% | · | |
| ROIC | · | · | -54.5% | -49.7% | -99.0% | -77.3% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.3 | 7.6 | 3.6 | 3.9 | · | |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 | 3.8 | · |
Efficiency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.1 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 5.1 | 10.1 | · |
Growth Rates 4
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | · | · | |
| Revenue CAGR 3Y | 5.2% | -10.1% | 11.7% | · | · | · | · | |
| Revenue CAGR 5Y | -13.0% | · | · | · | · | · | · | |
| Net Income YoY | · | · | -24.5% | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $4M | $16M | $5M | $6M | $11M | · | |
| Net Income TTM | $-147M | $-114M | $73M | $96M | $-98M | $-160M | · | |
| Market Cap | · | · | · | · | $16M | $21M | · | |
| P/E | -18.3 | -2.6 | -2.5 | -2.5 | -1.8 | · | · | |
| P/S | · | · | · | · | 2.9 | 1.9 | · | |
| P/B | · | · | · | · | 0.2 | 0.1 | · | |
| P / Tangible Book | · | 11.6 | · | · | 0.2 | 0.1 | · | |
| P / Cash Flow | · | · | · | · | -0.2 | -0.1 | · | |
| P / FCF | · | · | · | · | -0.2 | -0.1 | · | |
| Earnings Yield | -5.5% | -37.9% | -39.9% | -40.5% | -55.6% | · | · |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $700.0K | $900.0K | $644.0K | $3M | $2M | $800.0K | $511.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | |
| R&D Expense | $31M | $33M | $33M | $29M | $34M | $22M | $19M | $24M | $25M | $21M | $14M | $18M | $16M | $15M | $19M | $12M | |
| SG&A Expense | $15M | $10M | $11M | $7M | $8M | $6M | $5M | $7M | $9M | $8M | $6M | $9M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $51M | $49M | $46M | $37M | $43M | $27M | $24M | $31M | $35M | $30M | $21M | $27M | $23M | $20M | $25M | $19M | |
| Operating Income | $-51M | $-48M | $-45M | $-34M | $-41M | $-27M | $-24M | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M | |
| Pretax Income | $-50M | $-47M | $-44M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| Income Tax | $200.0K | $200.0K | $374.0K | $0 | $100.0K | $0 | $7.0K | $0 | $0 | $48.0K | $0 | $13.0K | $0 | $0 | $0 | $87.0K | |
| Net Income | $-50M | $-48M | $-45M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| EPS (Basic) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| EPS (Diluted) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| Shares (Basic) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| Shares (Diluted) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| EBITDA | $-51M | $-48M | · | $-34M | $-41M | $-27M | · | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M |
Balance Sheet 23
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175M | $229M | $194M | $70M | $103M | $13M | $32M | $46M | $66M | $102M | $149M | $174M | $192M | $213M | $248M | $74M | |
| Prepaid Expense | $10M | $2M | $3M | $3M | $2M | $4M | $2M | $2M | $3M | $2M | $3M | $4M | $2M | $4M | $4M | $3M | |
| Other Current Assets | $27M | $18M | $19M | $19M | $18M | $16M | $12M | $22M | $24M | $18M | $20M | $22M | $18M | $13M | $12M | $16M | |
| Current Assets | $202M | $247M | $213M | $89M | $121M | $29M | $44M | $69M | $90M | $120M | $169M | $196M | $210M | $226M | $260M | $90M | |
| PP&E (Net) | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $13M | $13M | $13M | $13M | $14M | $15M | $14M | $16M | $17M | |
| PP&E (Gross) | $33M | · | $33M | · | · | · | $29M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $23M | · | $23M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | $100.0K | $22.0K | $21.0K | $26.0K | $29.0K | $40.0K | $43.0K | $46.0K | $52.0K | $61.0K | $68.0K | $10.0K | $11.0K | $14.0K | $18.0K | |
| Other Non-current Assets | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $5M | $5M | $7M | $6M | $6M | $6M | $5M | $6M | $7M | |
| Total Assets | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Accounts Payable | $39M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $54M | $52M | $58M | $49M | $49M | $40M | $31M | $31M | $27M | $26M | $31M | $33M | $33M | $28M | $30M | $26M | |
| Capital Leases | $7M | $5M | $5M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $94.0K | $187.0K | $680.0K | $1M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $3M | $4M | $4M | $979.0K | $2M | $1M | |
| Total Liabilities | $63M | $58M | $65M | $58M | $57M | $48M | $38M | $39M | $35M | $34M | $46M | $53M | $54M | $36M | $41M | $36M | |
| Common Stock | $34M | $34M | $27M | $15M | $15M | $12M | $12M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $7M | |
| Paid-in Capital | $408M | $626M | $541M | $392M | $392M | $317M | $316M | $316M | $315M | $379M | $376M | $376M | $460M | $457M | $456M | $359M | |
| Retained Earnings | $-270M | $-441M | $-393M | $-348M | $-315M | $-313M | $-286M | $-263M | $-233M | $-266M | $-228M | $-211M | $-280M | $-220M | $-203M | $-275M | |
| Treasury Stock | $800.0K | $1M | $834.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $953.0K | $1M | |
| AOCI | $500.0K | $400.0K | $497.0K | $502.0K | $861.0K | $1M | $905.0K | $709.0K | $750.0K | $683.0K | $761.0K | $687.0K | $698.0K | $783.0K | $743.0K | $543.0K | |
| Stockholders' Equity | $160M | $208M | $169M | $53M | $86M | $3M | $27M | $54M | $79M | $112M | $144M | $164M | $179M | $212M | $244M | $82M | |
| Liabilities + Equity | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Shares Outstanding | · | · | · | 136,975,159 | 136,973,697 | 102,858,868 | · | · | · | · | · | · | · | · | · | · |
Cash Flow 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $2M | $2M | $516.0K | $1M | $2M | $-453.0K | $2M | $2M | $2M | $1M | $2M | $2M | $975.0K | $1M | $1M | |
| Operating Cash Flow | $-53M | $-49M | $-35M | $-32M | $-34M | $-20M | $-12M | $-22M | $-35M | $-35M | $-20M | $-26M | $-21M | $-20M | $-10M | $-1M | |
| CapEx | $400.0K | $400.0K | $373.0K | $117.0K | $32.0K | $0 | $-125.0K | $396.0K | $732.0K | $1M | $50.0K | $164.0K | $111.0K | $373.0K | $238.0K | $131.0K | |
| Investing Cash Flow | $-600.0K | $-300.0K | $-715.0K | $-241.0K | $-38.0K | $-400.0K | $793.0K | $-109.0K | $691.0K | $-2M | $-322.0K | $-341.0K | $42.0K | $152.0K | $-229.0K | $11.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $100.0K | $89M | $159M | $130.0K | $117M | $0 | $675.0K | $7.0K | $-33.0K | $-62.0K | $-837.0K | $8M | $-14.0K | $-818.0K | $195M | $-129.0K | |
| Net Change in Cash | $-54M | $35M | $124M | $-33M | $90M | $-20M | $-14M | $-20M | $-35M | $-40M | $-25M | $-18M | $-17M | $-35M | $174M | $-3M | |
| Free Cash Flow | · | $-50M | · | · | · | $-20M | · | · | · | $-36M | · | · | $-21M | · | · | $-2M |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| Net Margin | -7200.0% | -5288.9% | · | -1195.5% | -2858.4% | -3596.2% | · | -2839.7% | -2852.4% | -1943.5% | -705.6% | -1059.6% | -937.1% | -833.5% | -1506.8% | -656.2% | |
| Pretax Margin | -7171.4% | -5266.7% | · | -1195.5% | -2850.4% | -3596.2% | · | -2839.7% | -2852.4% | -1940.1% | -705.6% | -1059.0% | -937.1% | -833.5% | -1506.8% | -652.8% | |
| EBITDA Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| ROA | -27.5% | -30.0% | · | -32.6% | -32.5% | -27.6% | · | -21.5% | -20.0% | -14.4% | -7.6% | -9.7% | -11.7% | -8.2% | -9.5% | -9.9% | |
| ROE | -40.9% | -45.2% | · | -62.1% | -50.7% | -47.3% | · | -30.8% | -27.2% | -18.8% | -9.4% | -11.9% | -15.8% | -10.5% | -11.9% | -13.3% | |
| ROIC | -31.7% | -23.1% | · | -64.8% | -47.8% | -926.5% | · | -56.1% | -42.8% | -25.6% | -12.7% | -15.3% | -11.8% | -8.5% | -9.8% | -20.5% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.8 | · | 1.8 | 2.5 | 0.7 | · | 2.2 | 3.3 | 4.5 | 5.4 | 5.9 | 6.4 | 7.9 | 8.5 | 3.5 | |
| Quick Ratio | 3.2 | 4.4 | · | 1.4 | 2.1 | 0.3 | · | 1.5 | 2.4 | 3.8 | 4.7 | 5.2 | 5.9 | 7.5 | 8.1 | 2.8 |
Efficiency 1
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Valuation (TTM) 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $6M | · | $6M | $4M | $4M | · | $6M | $7M | $8M | $9M | $8M | $8M | $7M | $4M | $5M | |
| Net Income TTM | $-173M | $-150M | · | $-133M | $-133M | $-118M | · | $-108M | $-101M | $-89M | $-79M | $-85M | $-78M | $-81M | $-94M | $-101M | |
| Market Cap | · | · | · | $1.37B | $1.25B | $701M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -21.0 | -22.7 | · | -8.8 | -7.4 | -5.7 | · | -0.6 | -0.8 | -1.6 | -3.3 | -3.8 | -3.2 | -2.8 | -3.1 | · | |
| P/S | · | · | · | 225.9 | 281.9 | 159.7 | · | · | · | · | · | · | · | · | · | · | |
| P/B | · | · | · | 25.9 | 14.6 | 244.2 | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 25.9 | 14.6 | 246.7 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | · | · | · | · | -35.7 | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | · | · | · | · | · | -35.6 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.8% | -4.4% | · | -11.3% | -13.4% | -17.6% | · | -158.6% | -131.1% | -62.1% | -30.5% | -26.6% | -31.1% | -35.9% | -32.4% | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M |
| Operating Margin % | — | — | -486.0% | -1994.9% | -1727.6% |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M |
| Diluted EPS | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | — | — | 4.3 | 7.6 | 3.6 |
| Quick Ratio | — | — | 3.8 | 7.1 | 2.5 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | — | — | $-80M | $-56M | $-109M |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 78 filers · $297.4M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 18 (-11 vs prior Q) | 10 (0 vs prior Q) | 14 (+1 vs prior Q) | 24 (+12 vs prior Q) | -1.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | $60,127,058 | 3,666,284 | 20.22% | Shares |
| Siren, L.L.C. | $30,460,737 | 1,857,362 | 10.24% | Shares |
| Vivo Capital, LLC | $30,254,031 | 1,844,758 | 10.17% | Shares |
| PERCEPTIVE ADVISORS LLC | $27,114,940 | 1,653,350 | 9.12% | Shares |
| BAKER BROS. ADVISORS LP | $23,967,370 | 1,461,425 | 8.06% | Shares |
| Artisan Partners Limited Partnership | $22,514,756 | 1,372,851 | 7.57% | Shares |
| Logos Global Management LP | $15,006,000 | 915,000 | 5.05% | Shares |
| Patient Square Capital LP | $14,915,374 | 909,474 | 5.02% | Shares |
| Octagon Capital Advisors LP | $9,416,880 | 574,200 | 3.17% | Shares |
| ADAR1 Capital Management, LLC | $8,664,038 | 528,295 | 2.91% | Shares |
| Redmile Group, LLC | $6,731,216 | 410,440 | 2.26% | Shares |
| AMERIPRISE FINANCIAL INC | $6,200,315 | 378,068 | 2.09% | Shares |
| MILLENNIUM MANAGEMENT LLC | $4,391,641 | 267,783 | 1.48% | Shares |
| Elmind Capital, LP | $4,346,000 | 265,000 | 1.46% | Shares |
| Ishara Investments LP | $3,025,800 | 184,500 | 1.02% | Shares |
| Yiheng Capital Management, L.P. | $2,790,329 | 170,142 | 0.94% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $2,679,776 | 163,401 | 0.90% | Shares |
| GREAT POINT PARTNERS LLC | $2,573,258 | 156,906 | 0.87% | Shares |
| JANE STREET GROUP, LLC | $2,355,171 | 143,608 | 0.79% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $1,957,094 | 119,335 | 0.66% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $1,866,697 | 113,823 | 0.63% | Shares |
| Ikarian Capital, LLC | $1,690,953 | 525,000 | 0.57% | Shares |
| XTX Topco Ltd | $1,495,713 | 91,202 | 0.50% | Shares |
| DIVERSIFY WEALTH MANAGEMENT, LLC | $1,246,716 | 89,692 | 0.42% | Shares |
| Diversify Advisory Services, LLC | $1,246,716 | 89,692 | 0.42% | Shares |
| Dorsey Wright & Associates | $1,199,086 | 73,115 | 0.40% | Shares |
| Polymer Capital Management (HK) LTD | $1,057,800 | 64,500 | 0.36% | Shares |
| DEUTSCHE BANK AG\ | $971,536 | 59,240 | 0.33% | Shares |
| LPL Financial LLC | $881,516 | 53,751 | 0.30% | Shares |
| AdvisorShares Investments LLC | $716,073 | 43,663 | 0.24% | Shares |
| Cetera Investment Advisers | $578,215 | 35,257 | 0.19% | Shares |
| Engineers Gate Manager LP | $532,000 | 32,439 | 0.18% | Shares |
| Qube Research & Technologies Ltd | $472,402 | 28,805 | 0.16% | Shares |
| STIFEL FINANCIAL CORP | $452,774 | 27,608 | 0.15% | Shares |
| Russell Investments Group, Ltd. | $413,722 | 25,227 | 0.14% | Shares |
| CITADEL ADVISORS LLC | $373,625 | 22,782 | 0.13% | Shares |
| Burns Matteson Capital Management, LLC | $357,815 | 21,818 | 0.12% | Shares |
| Atria Investments, Inc | $309,993 | 18,902 | 0.10% | Shares |
| Persistent Asset Partners Ltd | $256,332 | 15,630 | 0.09% | Shares |
| PERSONAL CFO SOLUTIONS, LLC | $212,216 | 12,940 | 0.07% | Shares |
| Point72 Asset Management, L.P. | $199,227 | 12,148 | 0.07% | Shares |
| TWO SIGMA INVESTMENTS, LP | $190,732 | 11,630 | 0.06% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $189,813 | 11,574 | 0.06% | Shares |
| Integrated Wealth Concepts LLC | $170,053 | 10,369 | 0.06% | Shares |
| China Universal Asset Management Co., Ltd. | $131,200 | 8,000 | 0.04% | Shares |
| BARCLAYS PLC | $118,047 | 7,198 | 0.04% | Shares |
| Optiver Holding B.V. | $105,862 | 6,455 | 0.04% | Shares |
| UBS Group AG | $102,418 | 6,245 | 0.03% | Shares |
| RHUMBLINE ADVISERS | $92,014 | 5,611 | 0.03% | Shares |
| Truvestments Capital LLC | $63,829 | 3,892 | 0.02% | Shares |
| GAMMA Investing LLC | $46,445 | 2,832 | 0.02% | Shares |
| Allworth Financial LP | $27,602 | 1,683 | 0.01% | Shares |
| State of Wyoming | $23,698 | 1,445 | 0.01% | Shares |
| Rockefeller Capital Management L.P. | $20,434 | 1,246 | 0.01% | Shares |
| HM PAYSON & CO | $6,888 | 420 | 0.00% | Shares |
| Continuum Advisory, LLC | $6,560 | 400 | 0.00% | Shares |
| MORGAN STANLEY | $6,462 | 394 | 0.00% | Shares |
| Duquesne Family Office LLC | $6,287 | 383,363 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $5,936 | 362 | 0.00% | Shares |
| WELLS FARGO & COMPANY/MN | $4,920 | 300 | 0.00% | Shares |
| OSAIC HOLDINGS, INC. | $4,541 | 277 | 0.00% | Shares |
| Wilmington Savings Fund Society, FSB | $4,526 | 276 | 0.00% | Shares |
| NISA INVESTMENT ADVISORS, LLC | $3,280 | 200 | 0.00% | Shares |
| Farther Finance Advisors, LLC | $2,690 | 164 | 0.00% | Shares |
| HRT FINANCIAL LP | $2,479 | 151,197 | 0.00% | Shares |
| Federation des caisses Desjardins du Quebec | $2,378 | 145 | 0.00% | Shares |
| Silver Grove Financial Group, Inc. | $1,328 | 81 | 0.00% | Shares |
| Larson Financial Group LLC | $1,082 | 66 | 0.00% | Shares |
| Ascentis Wealth Management, LLC | $967 | 59 | 0.00% | Shares |
| SEI INVESTMENTS CO | $820 | 50 | 0.00% | Shares |
| Pinnacle Wealth Planning Services, Inc. | $656 | 40 | 0.00% | Shares |
| NATIONAL BANK OF CANADA /FI/ | $371 | 23 | 0.00% | Shares |
| Bell Investment Advisors, Inc | $345 | 21 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $320 | 20 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $213 | 13 | 0.00% | Shares |
| TRUST CO OF TOLEDO NA /OH/ | $164 | 10 | 0.00% | Shares |
| Stone House Investment Management, LLC | $148 | 9 | 0.00% | Shares |
| BlackRock, Inc. | $33 | 2 | 0.00% | Shares |
Company insiders 10 insiders · 4 officers · 3 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Daniel Tasse | Chief Executive Officer | Nov. 20, 2023 A | — | 0 | 0 | $0 |
| Virginie Boucinha | Chief Financial Officer | Nov. 20, 2023 A | 19,000 | 0 | 0 | $0 |
| Sebastien Robitaille | Chief Financial Officer | Nov. 21, 2022 A | 36,500 | 0 | 0 | $0 |
| Pharis Mohideen | Chief Medical Officer | July 29, 2026 S | 144,531 | 0 | 1 | $-1,253 |
| Timothy E Morris | Director | Aug. 25, 2023 P | 12,000 | 0 | 0 | $0 |
| Daniel B Soland | Director | Aug. 1, 2023 P | 20,000 | 0 | 0 | $0 |
| Adora Ndu | — | June 10, 2021 P | — | 0 | 0 | $0 |
| Viviane Monges | — | June 10, 2021 P | — | 0 | 0 | $0 |
| Madduri Ravin Rao | — | June 10, 2021 P | — | 0 | 0 | $0 |
| Michel De Rosen | — | June 10, 2021 P | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 filings | Jan. 14, 2026 | 9.99% | Amendment | — | SEC |
| Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 filings | Jan. 7, 2026 | 4.70% | Amendment | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| APIE · Trust for Professional Managers | 0.00% | 2,245 NS | May 31, 2026 | N-PORT |